Results 51 to 60 of about 47,017 (70)

45-day mortality after 467 779 knee replacements for osteoarthritis from the National Joint Registry for England and Wales: an observational study

Lancet, The, 2014
Linda P Hunt, Yoav Ben-Shlomo, Andrew Judge   +2 more
exaly  

Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma

Journal of Clinical Oncology, 2004
Michael B Atkins, Manuel Hidalgo, Walter M Stadler   +2 more
exaly  

CCI-779 Inhibits Rhabdomyosarcoma Xenograft Growth by an Antiangiogenic Mechanism Linked to the Targeting of mTOR/Hif-1α/VEGF Signaling

Neoplasia, 2006
Arnulfo Mendoza
exaly  

Targeting Apoptosis Pathways in Cancer Therapy

Ca-A Cancer Journal for Clinicians, 2005
Thomas E Witzig
exaly  

CCI‐779 in metastatic melanoma

Cancer, 2005
Kim A Margolin, James H Doroshow
exaly  

Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme

Investigational New Drugs, 2005
Patrick Wen, David Schiff, Kenneth Hess
exaly  

The rapamycin analog CCI-779 is a potent inhibitor of pancreatic cancer cell proliferation

Biochemical and Biophysical Research Communications, 2005
Donghui Li, James L Abbruzzese
exaly  

Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study

Journal of Clinical Oncology, 2005
Evanthia Galanis, Jan C Buckner, Karla V Ballman   +2 more
exaly  

Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs

Investigational New Drugs, 2004
Patrick Wen, David Schiff, Lisa M Deangelis   +2 more
exaly  

Phase II Study of Temsirolimus (CCI-779), a Novel Inhibitor of mTOR, in Heavily Pretreated Patients With Locally Advanced or Metastatic Breast Cancer

Journal of Clinical Oncology, 2005
Stephen Chan, Vladimir Semiglazov
exaly